Physician profile
John Champlin
NPI 1891865408
$2,526.59
in general payments reported to CMS, 2019-2025
31 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $927 · 2020: $285 · 2021: $419 · 2022: $333 · 2023: $179 · 2024: $140 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $563.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $368.61 | 2019-2025 | Botox |
| Pfizer INC. | $305.24 | 2019-2024 | |
| Lilly USA, LLC | $249.80 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Ipsen Biopharmaceuticals, INC | $180.30 | 2019-2023 | Dysport |
| Novo Nordisk INC | $165.54 | 2019-2023 | |
| Allergan, INC. | $140.73 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $107.77 | 2019-2025 | Belbuca |
| Scilex Pharmaceuticals INC. | $92.95 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.90 | 2019-2022 | |
| Exact Sciences Corporation | $91.87 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.39 | 2019-2023 | Relistor |
| Glaxosmithkline, LLC. | $76.23 | 2019-2021 | |
| Pacira Therapeutics, INC. | $75.27 | 2019 | |
| Fidia Pharma USA INC. | $65.19 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $55.96 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $50.05 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $43.28 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $41.93 | 2019 | |
| Si-Bone, INC. | $41.23 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $26.06 | 2022 | |
| Qol Medical, LLC | $24.60 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $23.62 | 2021 | |
| Arbor Pharmaceuticals, INC. | $21.05 | 2019 | |
| Idorsia Pharmaceuticals US INC | $20.45 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.60 | 2022 | |
| Sanofi Pasteur INC. | $16.51 | 2019 | |
| Boston Scientific Corporation | $15.63 | 2019 | |
| Assertio Therapeutics, INC. | $15.00 | 2019 | |
| Vanda Pharmaceuticals INC. | $13.83 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Champlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.